OKYO Pharma (STU:OK10) EBITDA Margin %: 0.00% (As of Sep. 2025)


STU:OK10 OKYO Pharma Ltd STU:OK10
23 GF Score
Price €2.16
! 3 Warning Signs
View Full Analysis

What is OKYO Pharma EBITDA Margin %?

OKYO Pharma STU:OK10 23 EBITDA Margin % is 0.00% as of Sep. 2025. GuruFocus rates STU:OK10 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, OKYO Pharma ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. OKYO Pharma's EBITDA for the six months ended in Sep. 2025 was €-2.13 Mil. OKYO Pharma's Revenue for the six months ended in Sep. 2025 was €0.00 Mil. Therefore, OKYO Pharma's EBITDA margin for the quarter that ended in Sep. 2025 was 0.00%.

OKYO Pharma  (STU:OK10) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

OKYO Pharma EBITDA Margin % Related Terms

OKYO Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma EBITDA Margin % Chart

OKYO Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OKYO Pharma Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:OK10 vs SGMO, AARD, ANIX: EBITDA Margin % Comparison

For the Biotechnology subindustry, OKYO Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OKYO Pharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's EBITDA Margin % falls into.


STU:OK10
23GF Score
OKYO Pharma Ltd STU:OK10
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OKYO Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

OKYO Pharma's EBITDA Margin % for the fiscal year that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2025 )/Revenue (A: Mar. 2025 )
=-6.565/0
= %

OKYO Pharma's EBITDA Margin % for the quarter that ended in Sep. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-2.131/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
OKYO Pharma (STU:OK10) has a EBITDA Margin % of 0.00% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OKYO Pharma and its competitors. According to the industry distribution chart, OKYO Pharma ranks #999999 out of 944 companies in the Biotechnology industry.
Is OKYO Pharma's EBITDA Margin % too high?
OKYO Pharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, OKYO Pharma ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's EBITDA Margin % compare to SGMO and AARD?
According to the Biotechnology industry distribution chart, OKYO Pharma ranks #999999 out of 944 companies for EBITDA Margin %. This places OKYO Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OKYO Pharma and its competitors. OKYO Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (STU:OK10) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For OKYO Pharma (STU:OK10), the current EBITDA Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Other Exchanges OKYO:USA
Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
23GF Score

Get the complete analysis for STU:OK10

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.16
Price